ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms of Diabetic Kidney Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 1147

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Internal Medicine II, Division of Nephrology, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
2. Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
3. Centre for Cognitive Research in Neuropsychiatric Pathology (Neuropsy-Cog), Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
4. Center for Translational Research and Systems Medicine, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
5. County Emergency Hospital Timisoara, 300723 Timisoara, Romania
Interests: chronic kidney disease; diabetic kidney disease; epigenetics; proteomics; lipidomics; metabolomics; mitochondrial dysfunction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetic kidney disease (DKD), as a major microvascular complication of both type 1 and type 2 diabetes mellitus (DM), accounts for over 40% of patients who reach end-stage renal disease and are referred to renal replacement therapies.

The tubulocentric concept with regard to DKD has emphasized the pivotal role of the proximal tubule and of the tubulointerstitial compartment in the development of DKD. The glomerular theory raises a similar interest, with a special focus on the contribution of podocyte injury in the course of DKD.

Chronic systemic inflammation and the role of inflammatory response in the development and progression of chronic kidney disease DKD have been highly recognized.

An inflammatory response which involves the innate immune system, as well as epigenetic mechanisms, plays an important role in the development of albuminuria in the course of type 2 DM. Particular molecular signatures and epigenetic profiles have emerged to support the complexity of DKD.

Mitochondrial dysfunction plays many specific roles in the pathogenesis of DKD. The importance of mitochondria in the pathogenesis of DKD resides in both the tubulocentric view and the mitochondria-centric view. Mitochondrial injury to glomerular endothelial cells and podocytes is also important for the development of DKD.

We are particularly taking interest in original papers and reviews that report the relevance of the molecular mechanisms involved in the pathogenesis of DKD.

Prof. Dr. Ligia Petrica
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetics
  • epigenetics
  • inflammation
  • mitochondrial dysfunction
  • proteomics
  • lipidomics
  • metabolomics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 932 KiB  
Review
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
by Alessio Mazzieri, Francesca Porcellati, Francesca Timio and Gianpaolo Reboldi
Int. J. Mol. Sci. 2024, 25(7), 3969; https://doi.org/10.3390/ijms25073969 - 03 Apr 2024
Viewed by 815
Abstract
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, [...] Read more.
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, oxidative stress, inflammatory pathway, fibrotic signaling, and hemodynamic mechanisms) appears to drive the onset and progression of DKD. A growing understanding of the pathogenetic mechanisms, and the development of new therapeutics, is opening the way for a new era of nephroprotection based on precision-medicine approaches. This review summarizes the therapeutic options linked to specific molecular mechanisms of DKD, including renin-angiotensin-aldosterone system blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, endothelin receptor antagonists, and aldosterone synthase inhibitors. In a new era of nephroprotection, these drugs, as pillars of personalized medicine, can improve renal outcomes and enhance the quality of life for individuals with DKD. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Diabetic Kidney Diseases)
Show Figures

Figure 1

Back to TopTop